Company DescriptionOtonomy is a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. This field represents a large opportunity as there are no approved drug treatments for the nearly 30 million Americans facing debilitating hearing and balance disorders such as Ménière’s disease, sudden sensorineural hearing loss, noise-induced hearing loss, age-related hearing impairment, and tinnitus.

Proceeds Purposesoceeds from the financing will support Otonomy’s first two programs through pivotal clinical studies as well as expansion of the Company’s pipeline of locally delivered drugs to treat disorders of the ear.